In This Section

Home / Learn / Presentations & Abstracts / Presentation Detail

Collaborative Learning Workshops to Optimize Integration of Cancer Immunotherapies in the Community Setting

Latha Shivakumar, PhD, CHCP
Director, Clinical Education Development
Association of Community Cancer Centers

Latha Shivakumar has a Ph.D. in Molecular and Cellular biology from The University of Texas Southwestern Medical Center and is a Certified Healthcare CPD Professional. She has 13 years of experience in the continuing medical education field and is currently the Director of Clinical Education Development at the Association of Community Cancer Centers (ACCC). In her current role, she is responsible for identifying educational needs among the ACCC members and developing innovative clinical educational programs to address these gaps.

Latha started her career in oncology research and transitioned to the continuing education field where she retained her focus on oncology. Most recently, she was the Director of Educational Development at The France Foundation, where she contributed to expanding their educational offerings in oncology and set up new collaborations with medical societies and academic centers. Prior to this, Latha has held educational development positions with accredited medical education providers including, Rockpointe corporation, Institute for Medical Education and Research, and Physicians Education Resource.

  May 31, 2019

Background: The expanding armamentarium of immunotherapies available to treat patients with cancer poses a significant challenge to community practitioners who have to navigate through several practical issues to provide immunotherapy safely and effectively in their own communities. The Association of Community Cancer Centers (ACCC) implemented two collaborative learning workshops aimed at providing guidance to the entire multidisciplinary cancer care team, including oncologists, oncology nurses, advanced practice providers and other healthcare professionals, on the best practices for implementing cancer immunotherapies in the community setting with respect to care coordination, monitoring and management of immune-related adverse events (irAEs), access to care, and patient engagement in shared decision-making.

Related Content